Intellikine Gets Two, Two, Two Partners In One With Infinity PI3 Kinase Deal
This article was originally published in The Pink Sheet Daily
Ex-U.S. commercialization comes along with the Infinity partnership through Infinity's "big brother" relationship with Mundipharma.
You may also be interested in...
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.